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REVIEW
Abstract: Epidemiologic evidence has shown that the worldwide prevalence of asthma is
increasing. The leukotriene receptor antagonists (LTRAs) represent a new class of therapy for
asthma. They have been developed in the last decade and play a pivotal steroid-sparing role in
treating the inflammatory component of asthma. Consequently, reports of Churg-Strauss
syndrome (CSS), a rare form of systemic vasculitis, have been recognized as a potential side
effect in individuals with moderate to severe asthma on LTRA therapy. The serious nature of
this disorder is worthy of prompt recognition by clinicians and aggressive therapy to avoid the
subsequent longstanding effects of vasculitis. To validate the postulated linkage between the
LTRAs and CSS, this review comprehensively evaluates reported cases in the literature and
supports a pathophysiological relationship between the LTRAs and the development of CSS.
Keywords: asthma, Churg-Strauss syndrome, leukotrienes, leukotriene receptor antagonists,
montelukast, zafirlukast
Introduction
Asthma is a chronic inflammatory disease associated with airflow obstruction that
results from contraction of airway smooth muscle, increased secretion of mucus,
mucosal edema, and infiltration of the airway wall by inflammatory cells, particularly
eosinophils. There is increasing evidence that leukotrienes (LTs), in particular the
cysteinyl leukotrienes (CysLTs), contribute to the pathophysiology of asthma
(Henderson 1994; Jones and Rodger 1999). Leukotrienes are produced by a number
of cells involved in the asthmatic response, including eosinophils, mast cells,
monocytes, and macrophages and they are found in bronchoalveolar lavage fluid of
asthmatics (Smith 1999). Their effects include bronchoconstriction, mucus secretion,
vascular permeability, decreased mucociliary clearance, edema, and eosinophil
recruitment to the airways, all of which culminate in chronic inflammation contributing
to airway remodeling (Jones and Rodger 1999; Hallstrand and Henderson 2002).
Leukotrienes
Discovery of LTs began over 60 years ago and they were originally termed “slow
reacting substance of anaphylaxis” (SRS-A) (Brocklehurst 1960). The chemical
components of SRS-A were later identified as the CysLTs, which are potent mediators
of airway smooth muscle contraction (Murphy et al 1979; Lewis et al 1980; Morris
et al 1980). The LTs are lipoxygenase products formed from the metabolism of
arachidonic acid (AA), an essential fatty acid found in the membrane of all cells
(Figure 1). The LTs are synthesized by the action of key enzyme 5-lipoxygenase
Deanna L McDanel1
Barbara A Muller2
1Departments of Pharmaceutical
Care and 2Internal Medicine,
University of Iowa Hospitals and
Clinics, Iowa City, IA, USA
Correspondence: Deanna L McDanel
Department of Pharmaceutical Care,
University of Iowa Hospitals and Clinics,
200 Hawkins Drive, CC101 GH, Iowa
City, IA 52242-1009, USA
Tel +1 319 384 5901
Fax +1 319 384 5843
Email deanna-mcdanel@uiowa.edu
The linkage between Churg-Strauss syndrome
and leukotriene receptor antagonists: fact or
fiction?Therapeutics and Clinical Risk Management 2005:1(2) 126
McDanel and Muller
(5-LO) on AA in the presence of 5-lipoxygenase-activating
protein (FLAP) (Devillier et al 1999a; Leff 2001; Hallstrand
and Henderson 2002). The biosynthesis of the LTs proceeds
as a result of the sequential catalytic actions on AA, forming
leukotriene A4 (LTA4), leukotriene B4 (LTB4), leukotriene
C4 (LTC4), leukotriene D4 (LTD4), and leukotriene E4 (LTE4).
Because LTC4, LTD4, and LTE4 all contain the amino acid
cysteine, they are collectively referred to as the cysteinyl
leukotrienes (Drazen et al 1999).
CysLT receptors
The non-cysteinyl LT, LTB4, binds to the B leukotriene
(BLT) receptor, which is responsible for recruitment and
activation of leukocytes, in particular neutrophils (Yokomizo
et al 1997; Devillier et al 1999a). Leukotriene B4 does not
appear to exert biological effects associated with asthma
and acts more as a chemotactic agent. On the other hand,
the cysteinyl LTs, LTC4, LTD4, and LTE4, are potent
recruiters for eosinophils in vivo and in vitro and have been
shown to mimic all the pathologic changes that are
characteristic of asthma. They mediate airway smooth
muscle constriction, chemotaxis, increased vascular
permeability, and mucus release (Figure 2) (Piper 1983; Hay
et al 1995; Hallstrand and Henderson 2002). The CysLTs
exert their biologic actions by binding to two CysLT
receptors, CysLT1 and CysLT2 (Devillier et al 1999a;
Hallstrand and Henderson 2002). However, most of the
actions of the CysLTs relevant to asthma are mediated
through CysLT1 receptor stimulation, which is stimulated
mostly by LTC4 and LTD4 (Piper 1983; Hallstrand and
Henderson 2002). The CysLT1 and CysLT2 receptors are
found on multiple sites, such as airway smooth muscle,
eosinophils, and macrophages (Figueroa et al 2001).
Leukotriene modifiers
The identification of SRS-A and the further detection of
the CysLTs lead to a revolution in drug discovery to identify
medications that could block the detrimental effects that
these mediators can have on asthma, specifically through
smooth airway constriction. Therefore, numerous
laboratories began developing medications that could be
used to inhibit these effects. A number of LT-modifier drugs
have been approved in the last two decades for the therapy
of asthma and represent the first new class of asthma
medications within the last 30 years (Jones and Rodger
1999).
The LT modifiers comprise two pharmacologic classes
of compounds, the leukotriene receptor antagonists (LTRAs)
and the 5-lipoxygenase (5-LO) pathway inhibitors, or
otherwise known as LT biosynthesis inhibitors. The LTRAs
block the CysLT1 receptor and thus block the biological
action of LTC4, LTD4, and LTE4. The first LTRA approved
for marketing was pranlukast in 1995 (Onon
®; Ono
Pharmaceutical Co, Ltd, Osaka City, Tokyo, Japan),
followed by montelukast in 1998 (Singulair
®; Merck & Co,
Inc, Whitehouse Station, New Jersey, USA), then zafirlukast
in 2001 (Accolate
®; AstraZeneca Pharmaceuticals LP,
Wilmington, Delaware, USA). The only approved LTRAs
in the United Stated are montelukast and zafirlukast.
Pranlukast is approved for use only in Japan. Zileuton
(Zyflo®; Abbott Laboratories, North Chicago, Illinois, USA)
Figure 1 Biochemical pathways of the formation and action of the leukotrienes
and sites of action of leukotriene modifying drugs. Source: Drazen JM, Israel E,
O’Byrne PM. 1999. Treatment of asthma with drugs modifying the leukotriene
pathway. N Engl J Med, 340:197–206. Reproduced with permission from the
Massachusetts Medical Society. Copyright © 2005 Massachusetts Medical Society.
All rights reserved.
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Figure 2 Potential sites and effects of cysteinyl leukotrienes relevant to a
pathophysiological role in asthma. Source: Hay DWP, Torphy TJ, Undem BJ. 1995.
Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends
Pharmacol Sci, 16:304–9. Reproduced with permission from Elsevier. Copyright ©
2005 Elsevier.Therapeutics and Clinical Risk Management 2005:1(2) 127
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is the only approved inhibitor of 5-LO in the United States
and it blocks the catalytic conversion of 5-lipoxygenase to
both the CysLTs and LTB4. It was approved for marketing
in1996, but Abbott Laboratories voluntarily withdrew it from
the market in June 2003. There have been no direct
comparisons between the two classes of agents, but the
evidence from clinical trials has shown that zileuton has no
therapeutic advantage over the LTRAs and is associated with
significant liver toxicity (Pauwels 1995).
A nonselective antagonist of CysLT1 and CysLT2 and
inhibitors of FLAP have been developed, but they are not
yet clinically available. Selective CysLT2 receptor
antagonists have not been developed. Leukotriene B4
receptor antagonists are also not clinically available because
they block experimentally-induced allergic airway
inflammation in animal models, but are ineffective in
blocking inflammation in patients with asthma (Hallstrand
and Henderson 2002).
LTRA role in asthma
An estimated 11 million Americans, or 5% of the general
population, were reported to have asthma in the year 2000
and many are not controlled with available bronchodilators
and corticosteroids (NAEPP 2002). As mentioned
previously, asthma is a chronic disease of the airways that
involves two basic processes: inflammation and broncho-
constriction. These processes lead to structural changes,
referred to collectively as airway remodeling. Airway
remodeling may or may not be a direct consequence of
airway inflammation. Airway inflammation consists of
eosinophils, activated Th2 lymphocytes that secrete
cytokines, monocytes, and mast cells. Airway remodeling,
alternatively, involves hyperplasia of goblet cells and smooth
muscle, subepithelial collagen deposition, submucosal gland
enlargement, and bronchial microvascular enlargement and
proliferation (Bradley et al 1991). As discussed, the LT
modifiers possess both bronchodilatory and anti-
inflammatory properties and, in addition, have been shown
to increase FEV1 and peak flow rates, and to reduce asthma
exacerbation rates, bronchial hyperresponsiveness, and
inflammatory markers. Therefore, the LT modifiers may
improve lung function and reduce symptoms in patients with
asthma (Smith 1999).
The National Asthma Education and Prevention Program
(NAEPP) Expert Panel from the National Heart, Lung, and
Blood Institute (NHLBI) of the National Institutes of Health
(NIH) has developed asthma guidelines. The guidelines were
published in 1991, updated in 1997, and then selected topics
were further updated in 2002 (NAEPP 1997, 2002). These
guidelines divide asthma severity into four categories: mild
intermittent (step 1), mild persistent (step 2), moderate
persistent (step 3), and severe persistent (step 4). These
severity grades allow for patient specific treatment based
on their severity of asthma symptoms. Inhaled cortico-
steroids (ICS) are widely used to treat patients with persistent
asthma and are first line treatments for steps 2 through 4.
Glucocorticosteroids (GCS) are considered potent
inhibitors of the synthesis of all arachidonic acid-derived
mediators, including the LTs and platelet-activating factor,
and decrease the synthesis of inflammatory prostanoids
(Devillier et al 1999b). However, there is data suggesting
that LT concentration is not significantly affected by GCS
use (Wenzel et al 1997; Pavord et al 1999). Some studies
have shown that the addition of LT modifiers to ICS
treatment may improve lung function and asthma control
(Devillier et al 1999a). In addition, using LT modifiers in
patients treated with high-dose (> 660 µg daily fluticasone
or > 1200 µg daily budesonide) ICS may allow up to a 50%
reduction of the steroids while maintaining clinical asthma
stability (Leff et al 1997; Tamaoki et al 1997). Also,
according to the 1997 guidelines, the LT modifiers were
considered as an alternative to low doses of ICS, cromolyn,
nedocromil, or theophylline for patients ≥ 12 years of age
with uncontrolled mild persistent asthma. At that time, the
guidelines mentioned that increased clinical experience and
further study in a wide range of patients was necessary to
establish a more specific role for LT modifiers in asthma
therapy (NAEPP 1997).
The 2002 asthma guideline updates have since been
published (NAEPP 2002). The most recent updates
continued the same role for LT modifiers in mild persistent
asthma, but added a role for them in moderate persistent
asthma as alternative add-on treatment in patients
inadequately controlled on low-to-medium dose (88–660 µg
daily fluticasone or 200–1200 µg daily budesonide) ICS in
place of long-acting inhaled beta2-agonists or theophylline.
The guidelines, however, still do not include the LT modifiers
in the treatment of severe persistent asthma. Furthermore,
they may have a role in patients with mild-to-moderate
asthma who have adverse effects (eg, dysphonia,
oropharyngeal candidiasis), or are adverse to ICS due to
the potential side effects. The LT modifiers are orally
administered and may increase adherence in patients who
are unable to utilize inhaled medications. In addition, they
provide once to twice daily dosing, have a quick onset of
action (1–4 hours), and are well tolerated. They may alsoTherapeutics and Clinical Risk Management 2005:1(2) 128
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be useful in treating patients with coexisting asthma and
allergic rhinitis, treating pediatric patients with asthma,
preventing exercise-induced asthma, treating aspirin-
sensitive asthma, reducing airway hyperresponsiveness to
an allergen bronchial challenge, and they may be of some
use in treating acute asthma exacerbations (Spector 1995;
Wilson et al 2000; Silverman et al 2004).
Overall, LT modifiers are considered safe and effective
in patients with mild to moderate persistent asthma to replace
ICS or as add-on therapy as an alternative to other
antiasthmatic medications. Yet, due to the onset of action
taking up to 4 hours and the prolonged duration of action of
the LTRAs, they should only be considered as maintenance
medications, as opposed to rescue medications, in the
treatment of asthma (Leff 2001). Therefore, patients with
mild or moderate persistent asthma who require maintenance
controller therapy may use LTRAs, but they should continue
using beta2-agonists as their primary rescue bronchodilatory
treatment. In addition, because LTRAs have been shown in
clinical trials to allow steroid tapering in patients on inhaled
and oral GCS, they may be highly desirable to patients
chronically taking GCS to reduce potential side effects from
prolonged administration of corticosteroids (Tamaoki et al
1997; Virchow et al 1997; Nayak et al 1998; Lofdahl et al
1999). Despite this benefit, there may be adverse effects in
asthmatics on combination therapy with LTRA and GCS
when the steroid dose is tapered.
Churg-Strauss syndrome
Churg-Strauss syndrome (CSS) is a rare disease with an
incidence of 1–2 cases per million persons per year in the
general population: this may range from 0.3 to 4 per million
persons per year (Kurland et al 1984; Watts et al 1995;
Guillevin et al 1999). However, CSS has been noted in
multiple patients receiving LTRA treatment in the
management of difficult to control moderate to severe
asthma. Most of the reported cases of CSS in patients on
LTRAs have occurred when patient’s steroids were being
gradually tapered or discontinued. Hence, it is unknown if
CSS is a direct effect of LT inhibition or if it is due to pre-
existing CSS being unmasked as a result of steroid
withdrawal. Therefore, further investigation into the
pathophysiologic linkage between CSS and use of LTRAs
is necessary.
Churg-Strauss syndrome, also known as allergic
granulomatosis and angiitis, is one of multiple vasculitic
diseases, termed the vasculitides. Vasculitis is a process
of endothelial inflammation of blood vessels, which
compromises the vessel lumen and can further result in tissue
ischemia and infarction leading to necrosis, or bleeding by
rupture of the blood vessel wall. Churg-Strauss syndrome
is a systemic vasculitis that affects mainly the medium- and
small-sized muscular arteries and is characterized with
coexisting asthma, allergic rhinitis, and prominent peripheral
blood eosinophilia (Lanham et al 1984). Churg-Strauss
syndrome afflicts multiple organ systems, predominantly
the pulmonary and cutaneous systems, causing pulmonary
infiltrates, purpura, urticaria, and nodules, respectively. It
may also be detrimental to the cardiovascular, nasal,
gastrointestinal, renal, musculoskeletal, and central nervous
systems. In addition, other constitutional symptoms may
be present, such as myalgias, weight loss, fever, malaise,
and headache (Guillevin et al 1999).
History and diagnosis
Jacob Churg and Lotte Strauss first described CSS in 1951,
when 13 patients with severe asthma were diagnosed with
allergic granulomatosis and angiitis (Churg and Strauss
1951). All of their patients had the following common
histological findings: blood and tissue eosinophilia,
necrotizing vasculitis, and necrotizing granulomas centered
on necrotic eosinophils. These illnesses predated
corticosteroid therapy, which is the preferred treatment for
CSS, and so only 2 patients survived. Some 30 years later,
Lanham et al (1984) reviewed 154 cases of CSS. They found
that CSS could be successfully treated with corticosteroids
and suggested to shift the diagnosis criteria from being
purely pathologic to being more clinically centered. They
proposed another classification system for CSS and were
also the first to propose that CSS develops in a phasic pattern
(Table 1). This sequential pattern may evolve with an early
“prodromal” or “pre-vasculitic” phase, a vasculitic phase,
and then finally a post-vasculitic phase. The prodromal phase
usually occurs in the second and third decades of life and
may be characterized by allergic rhinitis, followed by asthma
and the infiltration of the blood vessels and tissues by
eosinophils. Tissue eosinophilia is the diagnostic hallmark
of early-stage CSS and may progress to the life-threatening
vasculitic phase occurring mostly in the third and fourth
decades of life (Churg 2001). This stage may be fatal if not
treated promptly. The post-vasculitic phase may occur even
though patients are aggressively managed. In 1995, Churg
et al reaffirmed Lanham and colleagues’ concept of a phasic
evolution of CSS, where they reported 4 cases of asthmaTherapeutics and Clinical Risk Management 2005:1(2) 129
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and eosinophilia. These patients had varying degrees of
eosinophilic tissue infiltration, which either suggested or
confirmed vasculitis, and corticosteroid therapy for asthma
either partially or totally suppressed some of the
manifestations of CSS. They termed the incompletely
evolved illnesses as formes frustes CSS (Churg et al 1995).
In addition to the 1951 Churg and Strauss and 1984
Lanham et al criterion, as seen in Table 2, there are two
more recent sources that proposed more specific diagnostic
criteria for CSS, the American College of Rheumatology
(ACR) in 1990 and a Consensus Conference at the University
of North Carolina Chapel Hill in 1994 (Masi et al 1990;
Jennette et al 1994). The ACR criteria for classifying CSS
are the most common criteria used to diagnose it (Masi et al
1990). The presence of 4 or more of the following criteria
in a patient with documented vasculitis yields a sensitivity
of 85% and a specificity of 99.7% for CSS: (1) asthma;
(2) eosinophilia greater than 10% on differential white blood
cell count; (3) mononeuropathy (including multiplex) or
polyneuropathy; (4) migratory or transient pulmonary
infiltrates detected radiographically; (5) paranasal sinus
abnormality; and (6) biopsy containing a blood vessel with
extravascular eosinophils.
Since these criteria have been developed, antineutrophil
cytoplasmic antibody (ANCA) testing has become available
and is not part of any of these diagnostic schemes. A positive
ANCA is found in only 50%–70% of patients with CSS.
There are two diagnostically valuable types of ANCA:
antibodies against myeloperoxidase (MPO; p-ANCA or
perinuclear ANCA) and antibodies against a 29-kD
neutrophils serine protease, p29, or proteinase 3 (PR3;
c-ANCA or cytoplasmic ANCA) (Bielory et al 2001). A
positive p-ANCA is found in 30%–60% of patients with
CSS, while another 15% of patients have a positive c-ANCA.
A positive c-ANCA is more commonly positive in Wegener’s
granulomatosis, another vasculitic disease (Hoffman and
Specks 1998). A properly performed ANCA test must
include an antigen-specific immunoassay (ELISA) reacting
to neoantigens elaborated by the vasculitis process, which
are PR3 or MPO. An accurate diagnosis of CSS is difficult
because other individual manifestations of the syndrome
can occur independently and can exist for many years before
additional features become clinically apparent. In addition,
the main pathologic features of CSS, allergic granulo-
matosis, vasculitis, and eosinophilia, are also features of
several other diseases. Therefore, both clinical and
histopathologic diagnostic criteria should be used in
conjunction with an ANCA test for diagnosing CSS. These
confirmatory tests can provide strong support for an accurate
diagnosis of CSS, even if overt vasculitis cannot be found
pathologically (Churg 2001). Lastly, other laboratory tests
may help in the diagnosis, such as an erythrocyte
sedimentation rate, C-reactive protein, or eosinophil count.
Table 1 Phasic pattern of developing Churg-Strauss syndrome
Pre-vasculitic phase (prodromal) Vasculitic phase (eosinophilic) Post-vasculitic phase
Allergic rhinitis Peripheral and tissue eosinophilia End organ vasculitis
Sinusitis Pulmonary infiltrates Polyarthralgias
Asthma Eosinophilic gastroenteritis Peripheral neuropathy
Blood eosinophilia Necrotizing vasculitis Cerebral vasculitis (rare)
Tissue eosinophilia Necrotizing granulomas Constitutional symptoms
a
Myalgias and arthralgias Constitutional symptomsa
a Constitutional symptoms may include such things as fever, weight loss, malaise, decreased appetite, myalgias, or arthralgias.
Table 2 Diagnostic criteria for Churg-Strauss syndrome
Reference Criteria
Churg and Strauss 1951 History of asthma
Blood and tissue eosinophilia
Necrotizing vasculitis
Necrotizing granulomas centered on necrotic
eosinophils
Lanham et al 1984 Asthma
Peripheral blood eosinophilia (> 1.5 × 10
9/L)
Vasculitis involving ≥ 2 extrapulmonary
organs
American College of Asthma
Rheumatology  Eosinophilia > 10%
(Masi et al 1990) Mononeuropathy (including multiplex) or
polyneuropathy
Pulmonary infiltrates
Paranasal sinus abnormalities
Biopsy containing a blood vessel with
extravascular eosinophils
University of North Asthma
Carolina Chapel Hill Eosinophilia
Consensus Conference  Granulomatous inflammation involving the
(Jennette et al 1994) respiratory tract
Necrotizing vasculitisTherapeutics and Clinical Risk Management 2005:1(2) 130
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Epidemiology and etiology
The true incidence and epidemiology of CSS remains
unclear due to the difficulty in differentiating multiple
vasculitic processes into an accurate diagnosis of CSS or
formes frustes CSS. Approximately 10% of patients with
severe vasculitis are recognized to have CSS. Among the
major vasculitides, the frequency of CSS is second only to
that of Wegener’s granulomatosis (Specks and DeRemee
1990). It occurs in equal frequency between men and
women. The exact etiology of CSS is unknown, but it is
most likely due to an autoimmune process due to the
prominence of allergic features (allergic rhinitis and asthma),
heightened T cell immunity (pulmonary angiocentric
granulomatosis), altered humoral immunity (hypergamma-
globulinemia, especially IgE, and elevated rheumatoid
factor), and immune complex disease (vasculitis in the
presence of circulating IgE-containing immune complexes
and positive p-ANCA).
Treatment of CSS
Once CSS is diagnosed, the next clinical challenge is to
determine a treatment plan that will adequately treat the
vasculitis. Most patients with CSS have been treated with
oral or inhaled GCS for their asthma, and yet the mainstay
of treatment for CSS is corticosteroid therapy.
Corticosteroids
Treatment with corticosteroids dramatically alters the course
of CSS and improves overall survival. Doses usually start
at 1 mg/kg/d (usually 40–60 mg/d) and are tapered over
3–6 months to approximately 10 mg/d based on the patient’s
clinical response. The treatment is then continued for about
12 months or until CSS has completely resolved (Guillevin
et al 1996). Due to the poorer prognosis, if there is no
improvement with standard doses of corticosteroids in
patients with myocardial, gastrointestinal, or renal
involvement, than treatment with higher doses of cortico-
steroids, 1–1.5 mg/kg for longer periods of time, or the
addition of immunosuppressive agents is often warranted.
Inhaled steroids without the need for systemic GCS may be
useful for the management of upper and lower respiratory
tract disease. Long-term systemic corticosteroid therapy can
lead to complications, such as osteoporosis with bone
fracture, infection, hypercorticism, cataracts, psychosis,
hypertension, diabetes, and myopathy. Therefore, CSS
patients on long-term corticosteroid therapy are recom-
mended to take daily calcium supplements (1000–1500 mg
elemental calcium per day) to prevent bone loss. Patients
should be counseled appropriately and monitored for long-
term side effects.
Immunosuppressive therapy
Adjunctive immunosuppressive therapy with cyclo-
phosphamide or azathioprine to CSS has been shown to be
effective in some patients, possibly through an anti-
inflammatory process. Cyclophosphamide is dosed orally
at 2 mg/kg/d or intravenously at 0.6 g/m
2 monthly, both for
12 months. Cyclophosphamide use does not improve
survival rates, but its use is associated with a reduced
incidence of relapse and an improved clinical response to
treatment (Conron and Beynon 2000). Cyclophosphamide
therapy, however, is associated with hemorrhagic cystitis,
and urinalysis needs to be monitored periodically. If a patient
develops cystitis, they should get twice-yearly urinary
cytology and once-yearly cystoscopy due to the risk of
bladder cancer. On the other hand, azathioprine (AZA) is
less toxic than cyclophosphamide and yet provides similar
protection against relapse. Therefore, as soon as stable
remission is obtained, switching from cyclophosphamide
to AZA is currently recommended. The doses used for AZA
in CSS are similar to what is used in Wegener’s granulo-
matosis, and in most patients azathioprine is initially given
at a dose of 2 mg/kg/d (Jayne et al 2003). If remission is not
obtained within 6 months of cyclophosphamide in patients
with severe initial disease, then they should continue
cyclophosphamide until remission and for an additional few
months after remission, unless toxicity is limiting further
treatment. Methotrexate and mycophenolate mofetil are both
advocated as alternative immunosuppressive therapy, but
these agents have not been rigorously studied in treating
CSS (Jamaleddine et al 2002; Assaf et al 2004). In addition,
low-dose GCS (≤ 10 mg/d of prednisone) therapy is used
for an antiinflammatory effect while on immunosuppressive
therapy, but it has been suggested that concurrent use is not
necessary. Therefore, because GCS are not free of side
effects, it is recommended to slowly taper them off once
there is a significant response to the immunosuppressive
agent, which usually occurs after one month.
Other therapies
Alternative treatment options that have been used are high-
dose intravenous gamma globulin, interferon alpha,
cyclosporine, tumor necrosis factor (TNF)-alpha blockers,
and plasma exchange. These therapies are usually reservedTherapeutics and Clinical Risk Management 2005:1(2) 131
Churg-Strauss syndrome and LTRAs
for patients with severe, fulminant disease or in patients
unresponsive to corticosteroids and immunosuppressive
agents.
The use of high-dose intravenous immunoglobulin
(IVIG) treatment has been found to be beneficial in treating
CSS when other therapies fail. The mechanisms proposed
for the clinical response in CSS while on IVIG include the
following: increased perfusion around neurons may improve
neuropathy, enhanced neuromuscular transmission and
vasodilation may enhance cardiac function, and inactivation
of activated eosinophils may decrease eosinophilia
(Tsurikisawa et al 2004). Doses used in clinical studies
include 1–6 monthly treatments of IVIG between
400 mg/kg/d and 2 g/kg/d given daily for 5 days (Levy,
George, et al 1999; Levy, Sherer, et al 1999; Levy et al 2003;
Tsurikisawa et al 2004).
Interferon (IFN)-alpha is a cytokine that possesses potent
antiviral and immunoregulatory activities. Treatment with
IFN-alpha, either 2a or 2b, may be beneficial in patients
with CSS unresponsive to corticosteroids and cyclo-
phosphamide, with infectious complications, or with
prominent skin lesions, and may improve lung function.
(Tatsis et al 1998; Termeer et al 2001; Simon et al 2003).
Doses that were used in clinical studies range from 3 to 10
million units given 3 times per week, up to high doses such
as 3–9 million units/d. Treatment duration varied, but at
least 5 months of therapy was used in some studies (Simon
et al 2003).
Another alternative is the use of cyclosporine, which
has caused clinical remission and allowed discontinuation
in GCS therapy in one patient who failed previous
management with AZA and cyclophosphamide (McDermott
and Powell 1998). Though not widely studied, the use of
the TNF-alpha blockers, etanercept and infliximab, proved
to be effective and safe in treating patients who had a severe
relapse in their CSS and were refractory to
cyclophosphamide and corticosteroid therapy (Arbach et al
2002). Lastly, plasma exchange has been used in conjunction
with other therapies, and is designed for the removal of large
molecular weight substances from the plasma to reduce
further damage and permit reversal of the pathologic process.
However, a meta-analysis in CSS patients found that plasma
exchange added no benefit to treatment with corticosteroids,
with or without cyclophosphamide (Guillevin et al 1997).
Therefore, plasma exchange is not recommended routinely
for management of patients with CSS.
Monitoring treatment response
Monitoring the responsiveness of CSS to treatment and
recurrence/relapse of CSS is best achieved by following the
eosinophil count and erythrocyte sedimentation rate. A
persistent positive ANCA in CSS may be a marker of an
underlying disease process, but this does not reflect disease
activity adequately and should not be used to determine
changes in therapy. This was demonstrated in a retrospective
study of 53 patients with polyarteritis nodosa or CSS in
whom the persistence of a positive ANCA did not correlate
with an active underlying disease (Cohen et al 1995).
Radiographic manifestations may remain stable or may
rapidly regress with corticosteroid treatment. After
successful response to treatment, it is very rare to have a
relapse, and therefore treatment can be discontinued in most
patients. However, premature withdrawal of treatment can
result in recurrence and so caution should be taken with
deciding when to stop therapy for CSS.
Prognosis of CSS
The prognosis of patients with CSS is unclear, but treatment
may induce clinical remission in over 90% of patients and
significantly decrease mortality by increasing the 5-year
survival rate to > 70% (Guillevin et al 1999). However, 25%
of patients may relapse when corticosteroids are tapered
and over 50% of those untreated may die within 3 months.
The presence or absence of certain clinical features may
strongly correlate with a patient’s prognosis. The following
correlate to a poor prognosis: cardiac, gastrointestinal, or
central nervous system involvement, renal insufficiency with
serum creatinine concentration > 1.6 mg/dL, or proteinuria
> 1 g/d. A “five-factor score” based upon the above 5
prognostic criteria has been used to predict survival in CSS.
Guillevin et al (1996) reported the following 5-year mortality
figures based on one large series: 12% when none of the
five prognostic factors was present, 26% when one factor
was present, and 46% when three or more factors were
present. Of these 5 factors, the presence of significant cardiac
(eg, pericarditis, heart failure, myocardial infarction) or
gastrointestinal disease (eg, abdominal pain, diarrhea,
gastrointestinal bleeding, colitis) appears to be the strongest
indicator of increased mortality. Also, the shorter the
duration of asthma before the onset of vasculitis, the poorer
the prognosis. Most deaths result from complications of the
vasculitic phase of the disease, and are most commonly
due to cardiac failure, myocardial infarction, cerebralTherapeutics and Clinical Risk Management 2005:1(2) 132
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hemorrhage, renal failure, gastrointestinal bleeding, or status
asthmaticus.
CSS linkage to LTRA
Churg-Strauss syndrome is a rare disorder that has been
postulated to occur in patients treated with LTRAs for
asthma. It has been noted to develop in steroid-dependent
asthmatic patients where their oral GCS dose was reduced
as they were successfully being treated with the LTRA (ie,
Wechsler et al 1998; Kinoshita et al 1999; Michael and
Murphy 2003). However, though less frequently, this
syndrome has also occurred when a LTRA has been
substituted for inhaled corticosteroids, without a history of
oral steroid withdrawal (ie, Katz and Papernik 1998; Green
and Vayonis 1999; Franco and Artes 1999; Sabio et al 2001).
In fact, the labeling for zafirlukast was revised after the Food
and Drug Administration (FDA) received case reports of
CSS in patients on zafirlukast. It now states that reducing
the dose of oral steroids in patients concomitantly treated
with zafirlukast has been followed by rare occurrences of
eosinophilia, vasculitic rash, worsening pulmonary
symptoms, cardiac complications, and/or neuropathy
sometimes presenting as CSS (Formulary 1997). Multiple
theories have been hypothesized to explain the possible
linkage between CSS and the LTRAs, but no definitive
causal link has been established.
Theories
One proposed theory to explain the association between the
LTRAs and CSS is that a patient may have an underlying
subclinical form of CSS, or formes frustes, and instituting
therapy with LTRAs allows the tapering of GCS and thus
the development of full-blown CSS (Churg et al 1995).
Interestingly, a second theory is that CSS is an allergic
response to therapy with LTRAs, as CSS has been shown to
be a hypersensitivity reaction to different antibiotics (eg,
erythromycin, azithromycin, roxithromycin) (Dietz et al
1998; Katz and Papernik 1998). However, in the reported
cases through the year 2000 in patients on LTRA,
development of CSS happened from 2 days to 8 months
after the initiation of treatment with LTRAs, with most
patients being on the LTRA for at least 2 months, which is
an unusually long time for drug hypersensitivity to develop
(Jamaleddine et al 2002). A third theory is based on the
imbalance in leukotriene receptor stimulation (Katz and
Papernik 1998). As discussed previously, these agents block
the effects of the cysLTs (LTC4, LTD4, and LTE4) but do
not block the effect of LTB4, which is a chemoattractant for
eosinophils and neutrophils. Thus, it has been hypothesized
that LTRAs could have led to increased levels of eosinophils.
However, though occurring much less frequently than with
the LTRAs, CSS has been described in asthmatic patients
receiving zileuton (Weller 2001). Zileuton, is a 5-LO
inhibitor and thus inhibits the synthesis of LTB4 in addition
to the cysLTs. Knowing this makes this prior hypothesis
less credible. Regardless, there have been a large number
of published cases of CSS identified since the marketing of
the LTRAs (Weller 2001; Jamaleddine et al 2002).
Therefore, further discussion of a possible linkage is
imperative.
Incidence
The true incidence of developing CSS in patients on LTRAs
is unknown. However, an estimated incidence of CSS in
the asthmatic population receiving zafirlukast has been
reported by Wechsler et al, when citing data on file from
Zeneca Pharmaceuticals, as 60 cases per million asthmatics/
year (Wechsler et al 1999). Martin et al (1999) reported the
incidence of CSS in asthmatics exposed to three non-LTRA
asthma therapies (bambuterol, salmeterol, and nedocromil)
as 64.4 cases per million asthmatics/year. Therefore, the
incidence of CSS between asthmatics is similar whether or
not they have been treated with LTRAs. Though the annual
incidence of CSS in the general population may range up to
4.0 cases/million, the incidence of CSS in asthmatic patients
receiving LTRAs, or other asthma therapies, is 20-fold that
of the general population (Kurland et al 1984). This further
supports the theory that some asthmatic patients might have
preexisting CSS that is suppressed during asthma treatment
with corticosteroids.
Case discussion
In 1999, Guillevin et al published a review of 96 patients
with CSS between the years of 1963 and 1995, before
marketing the LTRA class of medications. The authors
focused on the clinical manifestations and prognostic factors
of CSS in these patients. Of the patients who had a detailed
clinical history (80 of the 96 patients), a majority of them
had evidence of allergy/atopy and asthma upon diagnosis
with CSS, and 33% had pulmonary infiltrates. The proposed
causes for the development of CSS were various antigenic
exposures, desensitization therapy for severe asthma, and
rapid discontinuation of oral corticosteroids prior to the onset
of vasculitis. The 60 survivors were maintained in remissionTherapeutics and Clinical Risk Management 2005:1(2) 133
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with chronic low dose oral corticosteroids or inhaled
corticosteroids.
Previously reported cases on CSS and the LTRAs
The review by Guillevin et al (1999) shows that there have
been numerous reports of CSS prior to the availability of
LTRAs. However, since the marketing of the LTRAs, there
have been an increasing number of reports of CSS, and
therefore a particular class-effect cannot be ruled out. At a
National Institute of Health (NIH) workshop in 2000,
representatives from the FDA presented preliminary findings
based on analyses of data from its Adverse Events Reporting
System (AERS) for cases of CSS and other eosinophilic
conditions associated with 5 asthma drugs (Weller 2001).
These products were zafirlukast, montelukast, zileuton,
fluticasone, and salmeterol. They reported on 165 case
reports, with 151 patients of whom met 2 or more of the
ACR criteria for CSS while on LT modifier therapy (unlike
4 criteria that are used for diagnosing CSS). Eighty-three
patients were taking zafirlukast (52 also received
fluticasone), 63 were taking montelukast (41 with
concomitant fluticasone), and 5 were patients taking the
5-LO inhibitor zileuton (2 with fluticasone use). In all, 94
patients had adequate information on prior oral GCS use.
Of these, 88% had developed CSS during GCS tapering,
while 12% had developed CSS with no prior use or with
distant (> 1 year) prior use of GCS.
In 2002, Jamaleddine et al published a review of all the
published cases of CSS in patients on LTRAs up through
October 2000, which totaled 23 cases (Jamaleddine et al
2002). Of the 23 patients discussed, 13 were treated with
zafirlukast, 9 were treated with montelukast, and 1 with
pranlukast. The onset of CSS occurred anywhere from 2
days to 8 months after starting treatment with LTRAs. They
reported that CSS developed during the tapering of oral or
inhaled steroids in 18 patients, while in 5 patients CSS
manifested without concurrent tapering of steroids. Despite
what the authors report, after further review of the cases, it
is thought that CSS developed in GCS tapering in only 14
patients, and 9 patients did not have GCS tapering at disease
onset. Five patients had formes frustes CSS, or at least 3 of
the ACR criteria for classifying CSS before LTRA treatment,
and these symptoms increased with concomitant steroid
tapering, and CSS was diagnosed within 3 months of starting
LTRAs. In regards to the ACR criteria, all 23 patients had
asthma treated with inhaled or oral corticosteroids, 22 had
peripheral eosinophilia, 12 had neuropathy, 21 had evidence
of pulmonary infiltrates on chest radiograph, 18 patients
had sinusitis or rhinitis, and histologic evidence of vasculitis
was found in 15 patients. In addition, 10 patients had
cardiomyopathy and 11 had cutaneous involvement.
Review and analysis of all published cases of CSS
and LTRAs
In addition to the multiple reports from the FDA’s AERS,
since Jamaleddine and colleagues’ review of cases through
October 2000, we identified 27 additional case reports
published in the literature of CSS in patients on montelukast,
zafirlukast, and pranlukast (1 of which was from Wechsler
et al in 1999 and was not discussed by Jamaleddine et al
2002). We also have had 3 patients of our own who have
been diagnosed with CSS while taking LTRA for their
asthma. All 53 patient cases are compared in Table 3 and
will be discussed in this paper.
Of the 53 cases reviewed, 16 patients were treated with
zafirlukast, 30 were treated with montelukast, 5 with
pranlukast, and 2 with more than one of these agents. The
age of onset of CSS ranged from 7–79 years old (mean age
47 years), with only 11 patients < 30 years of age. There
were 30 females and 23 males, therefore the distribution
between the genders is similar. The onset of CSS occurred
anywhere from 2 days to 4 years after starting treatment
with LTRAs, with onset of CSS within 7 months of LTRA
in 39 (74%) patients (within 4 months in 24 patients).
The majority of patients used corticosteroid therapy
before being diagnosed with CSS, but 4 patients have never
received either oral or inhaled GCS. Thirty-seven patients
had been treated with both oral and inhaled GCS for their
asthma (1 patient may not have gotten ICS), while 7 patients
had only been treated with ICS and 5 had only been treated
with oral GCS. In the patients who had been treated with
oral GCS, the time between the last oral GCS use and the
diagnosis of CSS ranged from 3 days to 16 months, with 22
(42%) patients stopping GCS in the preceding 3 months.
However, this was not specified in 2 patients. Regarding
the relationship of CSS to tapering corticosteroids, 21 (40%)
patients began to manifest CSS during the tapering of oral
or inhaled steroids, while 31 (58%) patients began to
manifest CSS without concurrent tapering of steroids (in 1
patient it was not specified). In 5 patients, CSS was
diagnosed while they were still on oral GCS, which were
not being tapered in 3 patients.
The course of developing CSS while on LTRAs varied
between patients. Eight (15%) patients had at least 3 of the
ACR criteria for classifying CSS before LTRA treatment,
and therefore may have had formes frustes CSS, and theTherapeutics and Clinical Risk Management 2005:1(2) 134
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CSS symptoms increased in all 8 patients while on LTRA
therapy. The diagnosis of CSS occurred during the tapering
of GCS in 5 of the 8 patients with possible latent CSS.
Interestingly, 2 patients had the diagnosis of CSS prior to
starting the LTRA. One patient had a relapse of CSS within
1 week of starting montelukast and required an increase in
the GCS and cyclophosphamide doses (Solans et al 2002),
while the other patient did not have any increase in
symptoms even after 1 year of montelukast therapy
(Kalyoncu et al 2001). Also, one patient diagnosed with
CSS after 2 days of zafirlukast therapy was started on
zileuton 3 months after the diagnosis. There was no flare of
CSS symptoms while on approximately 9 months of zileuton
(Holloway et al 1998).
The clinical presentation, manifestations, and diagnosis
of CSS were clearly individualized between patients. In
regards to the ACR diagnostic criteria, all 53 patients had
asthma, 51 (96%) had peripheral eosinophilia, 29 (55%)
had neuropathy, 39 (74%) had evidence of pulmonary
infiltrates on chest radiograph, 38 (72%) patients had
paranasal sinus abnormality (ie, sinusitis or rhinitis), and
37 (70%) patients had biopsy evidence of vasculitis. A total
of 42 (79%) patients had constitutional symptoms, including
28 patients with fever, 23 with myalgias, 13 with arthralgias,
12 with malaise, and weight loss was significant in 3 patients.
Thirty-four (64%) patients had other organ involvement,
and included 23 patients with cutaneous (eg, rash), 17
patients with cardiovascular, 6 patients with gastrointestinal,
5 with renal, and 1 patient with gallbladder involvement.
Antineutrophil cytoplasmic antibody testing was used
in conjunction with both clinical and histopathologic
diagnostic criteria in 36 patients. Fourteen patients had a
positive ANCA test, that was specified in 9 with a (+) p-
ANCA, 1 had a (+) c-ANCA, and 1 had both a (+) p- and
(+) c-ANCA (reported as a false positive in 1 patient).
Otherwise, 21 had a negative test, that was specified in 2
with a (–) p-ANCA, 2 had a (–) c-ANCA, and 5 had both a
(–) p- and (–) c-ANCA. Ten patients had a reported elevated
CRP (normal < 5–10 mg/L) and 31 patients had a reported
elevated ESR (normal 0–13 mm/h). Of the 51 patients in
which therapy for CSS was reported, all patients received
GCS. Sixteen (31%) patients required additional
immunosuppressive therapy for the CSS, and 12 were treated
with cyclophosphamide (1 of which was on this prior and
had the dose increased), 1 with azathioprine, 1 with
cyclophosphamide for 10 days and switched to azathioprine,
and 2 with methotrexate. Also, 1 patient had IVIG therapy
for 1 year.
Lastly, Keogh and Specks (2003) conducted an
observational study in a large series of patients with CSS to
determine the association of leukotriene receptor antagonists
with the course of CSS and ANCA with disease activity.
They identified 91 patients by a computerized search of the
Mayo Clinic Rochester database for the years 1990 to 2000.
Twenty-three patients (25%) received LTRAs (7 received
montelukast, 16 received zafirlukast, and 2 received both)
during the course of CSS. Of the 23 patients on LTRAs, 16
received treatment before CSS was diagnosed, 6 started
LTRA in the course of CSS, and the time of use of the LTRA
was unclear in 1 patient. Only 3 of the 16 patients treated
with LTRA before CSS was diagnosed, had evidence of
formes frustes CSS before starting LTRAs. In the 13 patients
who received LTRA before the onset of symptoms, 8
developed CSS within 5 months (2 on LTRA >1 year) and
3 discontinued therapy at least 6 months before the onset of
CSS. Vasculitis was related to tapering CSS on only 2 of
the patients. Of the 6 patients who started LTRA therapy
during remission of CSS, 4 remained in remission, but 2
developed a vasculitic relapse in association with tapering
GCS.
Discussion
This article reviews all of the published cases identified by
the authors of CSS in patients taking LTRAs for the purpose
of further delineating if a linkage exists. From our analysis
of these cases, a possible linkage is supported by the
association between the use of GCS and course of disease
development while on LTRAs.
An editorial by Masi and Hamilos, published in the same
issue as the Jamaleddine et al review in 2002, further
interprets the available data on the complex relationships
between the LTRAs and the development of CSS (Masi and
Hamilos 2002). The authors proposed categorizing the cases
into 4 subgroups (category A, B, C, and D) as a way to
assess the case reports. These subgroups are based on the
temporal relationships between corticosteroid therapy,
initiation of LTRA therapy, and onset of CSS. Category A
included cases in which the CSS manifestations began while
on LTRAs, but in the absence of GCS therapy or without
any basic change in the asthma management while on LTRA
(ie, tapering or discontinuation of GCS). This category could
support a role for LTRAs in the evolution of CSS. Category
B included patients who began to manifest CSS after
receiving a LTRA in the setting of either tapering or
discontinuing oral or inhaled GCS therapy. The majority ofTherapeutics and Clinical Risk Management 2005:1(2) 137
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cases reported by Jamaleddine et al (2002) fit into this
category. Category C would include cases in which LTRAs
were started in patients in the course of latent CSS, such
that the patients have initial manifestations of formes frustes
CSS, or CSS in remission, even without any concurrent GCS
therapy or tapering/discontinuation of oral or inhaled GCS.
This category of patients would suggest that the use of
LTRAs was coincidental in that the drug was started in the
course of evolving disease. Category D is similar to category
C, and would include patients with formes frustes CSS
already present before starting LTRAs, except that CSS
occurs in the setting of a tapering or discontinuation of either
systemic or inhaled GCS therapy. It is most likely that these
cases already had formes frustes CSS and this was unmasked
by tapering the GCS rather than by the use of LTRAs.
Patients in category C or D should no longer be considered
as LTRA-induced CSS.
Compilation of the 53 cases discussed and categorizing
them via the Masi and Hamilos categories may help in
answering the question about a potential linkage between
LTRA and CSS (Figure 3; Table 3). It is shown that 26 (49%)
patients could be classified into category A and because there
were no changes or tapering in GCS therapy, there may have
been an independent association between LTRAs and CSS.
In contrast, 17 (32%) patients are classified in category B
and after receiving a LTRA, developed CSS during the
tapering or discontinuation of GCS therapy. This category
of patients may support the theory that the patient had an
underlying preexisting form of CSS, characterized by a
history of asthma and sinusitis/rhinitis in the majority of
patients, and that the development of the full-blown
syndrome coincidentally occurred after the introduction of
LTRAs. Of the 10 (18%) patients with 3 or more ACR
criteria prior to starting LTRA, 6 patients could be put in
category C as they did not have concurrent GCS tapering,
and 4 patients could be placed in category D as the full
manifestation of CSS occurred during GCS tapering. It may
be said with some confidence that CSS was not induced by
LTRA in these last 10 patients, as it is likely they did have
an underlying latent form of CSS.
Since the marketing of the LTRA in 1998, over 200 cases
total of CSS in patients taking LTRAs have been reported
in the literature, through the FDA’s AERS, and in an
observational study (Weller 2001; Keogh and Specks 2003).
From this paper, it is shown that nearly 50% of published
cases have shown that CSS manifests without tapering or
discontinuation of GCS therapy, and therefore it can be said,
though with a high degree of suspicion, that CSS may be a
LTRA-induced consequence and that there may be higher
risk in a select population of patients. However, with this
said, it should also be mentioned that though there have
been numerous cases of CSS in patients taking LTRAs,
millions of asthmatic patients are effectively being treated
with LTRAs. Therefore, the overall risk of developing CSS,
if truly linked to the LTRAs, is small and occurs only in a
minority of patients. The possible linkage, however, does
deserve consideration by clinicians.
Clinical impact
Leukotriene-receptor antagonists are effective and
reasonably safe agents to improve asthma control in patients
uncontrolled on GCS therapy and may permit the tapering
of systemic and inhaled GCS (Tamaoki et al 1997; Leff et
al 1997; Spector 2001). However, the incidence of CSS is
increasing and though no definitive link has been
established, there have been numerous case reports of
developing CSS while tapering or discontinuing oral or
inhaled GCS in patients on LTRA therapy for moderate to
severe persistent asthma, as seen in Table 3 (Watts et al
2000). One potential explanation of the increased incidence
of CSS is that patients with latent CSS might be more likely
to be treated with LTRAs, as a newer class of asthma therapy,
due to the refractoriness and severity of their current asthma.
On the other hand, there have also been multiple reports of
CSS developing in patients taking LTRAs without
concurrent GCS therapy or independent of GCS tapering/
Figure 3 Categorization of cases based on the categories described by Masi
and Hamilos (2002). Category A is when Churg-Strauss syndrome (CSS)
manifestations began while on leukotriene receptor antagonists (LTRAs), but in
the absence of glucocorticosteroid (GCS) therapy or without any basic change
in the asthma management. Category B is when CSS manifested after receiving a
LTRA in the setting of either tapering or discontinuing oral or inhaled GCS
therapy. Category C is when LTRAs were started in the course of latent CSS,
even without any concurrent GCS therapy or tapering/discontinuation of oral or
inhaled GCS. Category D is when LTRAs were started in the course of latent
CSS and GCS were being tapered or discontinued.Therapeutics and Clinical Risk Management 2005:1(2) 138
McDanel and Muller
discontinuation. Therefore, the association of CSS with the
use of LTAs may be coincidental, yet the possibility of a
direct linkage cannot be excluded. Until more definitive
controlled clinical or epidemiologic data are available,
prescribers should take into account the potential cause and
effect relationship as described prior to initiating LTRAs in
asthmatic patients.
Churg-Strauss syndrome should be suspected in patients
with constitutional symptoms, such as fever, weight loss,
malaise, or with increasing cough/dyspnea with decline in
pulmonary function, pulmonary infiltrates in the absence
of infection, eosinophilia, cardiac involvement, peripheral
neuropathy, glomerulonephritis, or palpable purpura.
Patients with any of these signs should be fully evaluated
for the potential diagnosis of CSS. Diagnosing CSS is
difficult, because there is no single definitive diagnostic test,
yet using both clinical and histopathologic criteria in addition
to a properly performed ANCA test and other lab tests (eg,
erythrocyte sedimentation rate, C-reactive protein, and
eosinophil counts) may provide substantial evidence for a
diagnosis of CSS (Churg 2001). If either formes frustes CSS
(Churg et al 1995) or advanced CSS is diagnosed and the
patient is taking a LTRA, discontinuing the LTRA is
recommended until further research can exclude with
confidence a definitive linkage in the evolution of CSS.
Early recognition and treatment of CSS is essential for
long-term survival and to maintain quality of life. The careful
diagnosis and thorough understanding of CSS will enable
clinicians to make sound treatment decisions and to provide
effective care for patients with this disease.
Summary
The authors conclude that the data are suggestive of a causal
linkage between LTRAs and the development of CSS.
However, without prospective clinical studies, current
evidence does not support a definitive association between
the development of CSS and LTRA therapy. The data does
suggest that the development of CSS in asthmatic patients
receiving LTRAs may occur as a result of tapering
corticosteroids, specifically in patients who may already
have a preexisting masked form of underlying vasculitis.
Healthcare providers should be aware of the warning signs
of vasculitis, especially in patients with 3 or more ACR
criteria that may be suggestive of formes frustes CSS, when
treating atopic patients. Based on this review, the authors
do not feel that clinicians should refrain from using LTRAs
in treating asthma, as they provide a very effective treatment
option. However, clinicians should monitor patients closely
for the constellation of symptoms suggestive of latent or
new onset CSS, which may occur concurrent with LTRA
therapy and GCS tapering or discontinuation in moderate-
to-severe asthmatics.
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